CRANFORD, N.J., Feb. 25, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company focused on adjunctive cancer care
and critical care drug products, today cited independent research
on the incidence of catheter-related blood stream infections
(CRBSIs) in the world.
DelveInsight had previously published a report on the incidence
of CRBSI in North America, five
European countries and Japan. This
new report adds the major areas from the rest of the world (ROW).
The report also provides an overview of various treatment
practices, and CRBSI epidemiology segmented by the global major
markets. The key findings were as follows:
- Total Incident Population of Catheter Related Bloodstream
Infection (CRBSI) in the Global* market was found to be 4,114,882
in 2017 and expected to reach up to 4,228,815 in 2028.
- Among the North America
countries, United States had the
highest incident population of CRBSI with 328,107 cases in
2017.
- Total incident population of CRBSI in APAC region was found to
be 3,105,930 cases in 2017; India
accounted for highest number of cases among all the APAC
countries.
- Among LATAM region, Brazil
accounted for highest incidence of CRBSI with 163,405 cases in
2017.
- In MENA region, Saudi Arabia
shows higher incidence of CRBSI with 28,118 cases in 2017 and
28,853 cases in 2028.
*Global: United States;
EU5 (Germany, France, Italy, Spain,
UK); APAC (Japan, China, India,
South Korea, Taiwan and Australia); LATAM (Argentina, Brazil, Mexico and Colombia); Middle
East (Saudi Arabia and UAE)
and Russia.
"These data begin to show the extreme impact of catheter related
bacteremia. The numbers are huge and we believe they are
under-reported," said Myron
Holubiak, the Chief Executive Officer of Citius. "Mino-Lok
is the only treatment under investigation designed to salvage the
contaminated catheter and preserve vascular access in patients with
CRBSI, thus sparing the patient the challenges and risks of
catheter removal and replacement. As has been reported previously,
Mino-Lok is at the midway point of its phase 3 study in the US
having passed the futility analysis; we believe that our study will
be a major contribution to the study of CRBSI and the utility of
antibiotic locks. More alternatives are needed to the practice of
removing and replacing infected central venous lines."
About Citius Pharmaceuticals, Inc.
Citius is a
specialty pharmaceutical company dedicated to the development and
commercialization of critical care products, with a focus on
anti-infectives, cancer care and unique prescription products that
use innovative, patented or proprietary formulations of
previously-approved active pharmaceutical ingredients. We seek to
achieve leading market positions by providing therapeutic products
that address unmet medical needs; by using previously approved
drugs with substantial safety and efficacy data, we seek to reduce
the risks associated with pharmaceutical product development and
regulatory requirements. Citius develops products that have
intellectual property protection and competitive advantages to
existing therapeutic approaches. For more information, please visit
www.citiuspharma.com.
About Mino-Lok®
Mino-Lok® is an
antibiotic lock solution being developed as an adjunctive therapy
in patients with central line-associated bloodstream
infections (CLABSIs) or catheter-related bloodstream infections
(CRBSIs). CLABSIs/CRBSIs are very serious, especially in
cancer patients receiving therapy through central venous catheters
(CVCs) and in hemodialysis patients where venous access presents a
challenge. There are currently no approved therapies to salvage
infected CVCs.
About DelveInsight
DelveInsight is a Business
Consultant company and serves as a Knowledge partner across the
value chain of the Pharmaceutical Industry. With the use of
proprietary databases and analytical models, DelveInsight provides
cutting-edge market and pipeline analysis and API intelligence
across all therapy areas to the Pharma and biotech sector, helping
clients to quantify market events and evaluate their impact on the
valuation of products, portfolios, and companies. Additional
information is available at www.delveinsight.com.
DelveInsight's "Catheter-Related Blood Stream Infections
(CRBSI)-Market Insights, Epidemiology & Market Forecast–2028"
report provides an overview of the disease and market size of CRBSI
for the global major pharmaceutical markets i.e., the United States, EU5 (Germany, France, Italy, Spain,
and the UK), Japan, APAC
(China, India, Taiwan, South
Korea and Australia), LATAM
(Brazil, Mexico, Argentina, Colombia and Russia) and Middle
East (Saudi Arabia and
United Arab Emirates). This report
covers the overview, various treatment practices, and CRBSI
epidemiology from 2017 to 2028, segmented by the global major
markets.
Safe Harbor
This press release may contain
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are made based on our
expectations and beliefs concerning future events impacting Citius.
You can identify these statements by the fact that they use words
such as "will," "anticipate," "estimate," "expect," "should," and
"may" and other words and terms of similar meaning or use of future
dates. Forward-looking statements are based on management's current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price.
Factors that could cause actual results to differ materially
from those currently anticipated are: the estimated markets for our
product candidates, including those in the DelveInsight report, and
the acceptance thereof by any market; risks associated with
conducting our Phase III trial for Mino-Lok, including completing
patient enrollment; our need for substantial additional funds;
risks relating to the results of research and development
activities; risks associated with developing Mino-Wrap, including
that preclinical results may not be predictive of clinical results
and our ability to file an IND; uncertainties relating to
preclinical and clinical testing; the early stage of products under
development; risks related to our growth strategy; our ability to
obtain, perform under and maintain financing and strategic
agreements and relationships; our ability to identify, acquire,
close and integrate product candidates and companies successfully
and on a timely basis; our ability to attract, integrate, and
retain key personnel; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
Contact:
Andrew
Scott
Vice President, Corporate Development
(O) 908-967-6677
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-cites-independent-estimates-of-total-available-world-market-for-mino-lok-301010555.html
SOURCE Citius Pharmaceuticals, Inc.